Novo Nordisk A/S (NYSE:NVO) was the target of some unusual options trading on Monday. Stock traders bought 1,686 put options on the company. This is an increase of approximately 1,353% compared to the typical volume of 116 put options.

Shares of Novo Nordisk A/S (NYSE:NVO) opened at $52.07 on Thursday. The firm has a market capitalization of $130,152.00, a P/E ratio of 22.29, a P/E/G ratio of 3.05 and a beta of 0.63. Novo Nordisk A/S has a 52 week low of $32.83 and a 52 week high of $52.45.

NVO has been the topic of a number of research analyst reports. Zacks Investment Research downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, October 9th. Bank of America upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. BNP Paribas downgraded Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Morgan Stanley upgraded Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a report on Friday, December 1st. Finally, BidaskClub upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Three analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $55.00.

In other Novo Nordisk A/S news, insider Eric S. Sprott purchased 50,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was acquired at an average price of $8.34 per share, with a total value of $417,000.00.

Several institutional investors have recently bought and sold shares of NVO. Geode Capital Management LLC boosted its stake in Novo Nordisk A/S by 20.6% during the 1st quarter. Geode Capital Management LLC now owns 28,778 shares of the company’s stock valued at $985,000 after purchasing an additional 4,910 shares during the last quarter. Bank of Montreal Can boosted its stake in Novo Nordisk A/S by 24.2% during the 2nd quarter. Bank of Montreal Can now owns 80,934 shares of the company’s stock valued at $3,470,000 after purchasing an additional 15,756 shares during the last quarter. Harbour Capital Advisors LLC boosted its stake in Novo Nordisk A/S by 4,188.9% during the 2nd quarter. Harbour Capital Advisors LLC now owns 22,088 shares of the company’s stock valued at $515,000 after purchasing an additional 21,573 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in Novo Nordisk A/S by 53.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 43,164 shares of the company’s stock valued at $1,851,000 after purchasing an additional 14,999 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in Novo Nordisk A/S by 0.7% during the 2nd quarter. Bessemer Group Inc. now owns 33,388 shares of the company’s stock valued at $1,431,000 after purchasing an additional 247 shares during the last quarter. Institutional investors own 6.18% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/07/investors-purchase-high-volume-of-put-options-on-novo-nordisk-as-nvo.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.